(Q34229084)

31 July 2017

1 reference

title

Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza (English)

1 reference

31 July 2017

1 reference

1 reference

Dreitlein WB

1

1 reference

31 July 2017

Maratos J

series ordinal

2

1 reference

31 July 2017

Brocavich J

series ordinal

3

1 reference

31 July 2017

language of work or name

1 reference

1 March 2001

1 reference

31 July 2017

published in

Clinical Therapeutics

1 reference

31 July 2017

volume

23

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

327-355

1 reference

Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

The importance of virus drug-resistance in the treatment of influenza with rimantadine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Implications of viral resistance to amantadine in control of influenza A

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Low incidence of rimantadine resistance in field isolates of influenza A viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Influenza virus neuraminidase: structure, antibodies, and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

New approaches to influenza chemotherapy. Neuraminidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Structure of the catalytic and antigenic sites in influenza virus neuraminidase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Disarming flu viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Rational design of potent sialidase-based inhibitors of influenza virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

The low potential for drug interactions with zanamivir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Effect of renal impairment on the pharmacokinetics of intravenous zanamivir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Respiratory distress associated with zanamivir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980042-4

7 January 2021

10.1016/S0149-2918(01)80042-4

Identifiers

DOI

1 reference

31 July 2017

1 reference